-
effectivehealthcare.ahrq.gov/products/form/bereaved-persons/sead
-
effectivehealthcare.ahrq.gov/products/form/attention-deficit-hyperactivity-disorder
-
effectivehealthcare.ahrq.gov/products/form/racial-disparities-health-healthcare/sead
-
effectivehealthcare.ahrq.gov/products/form/obsessive-compulsive-disorder/sead
-
effectivehealthcare.ahrq.gov/products/form/anal-cancer-treatment/sead
-
effectivehealthcare.ahrq.gov/products/form/ems-911-workforce-infection-control
-
effectivehealthcare.ahrq.gov/products/form/people-with-disabilities/sead
-
effectivehealthcare.ahrq.gov/products/form/carbohydrate-intake
-
effectivehealthcare.ahrq.gov/products/form/peripheral-nerve-blocks/sead
-
effectivehealthcare.ahrq.gov/products/form/cell-free-dna/sead
-
effectivehealthcare.ahrq.gov/products/form/disruptive-behavior/sead
-
effectivehealthcare.ahrq.gov/products/stakeholder-assessment-cer-needs-medicaid/abstract
January 04, 2013 - Expected Outputs: Submission of 10 fully developed priority research topics for Medicaid populations
-
effectivehealthcare.ahrq.gov/sites/default/files/substanceabuse_hi_impact.pdf
January 01, 2012 - October 2011 about preparing its new drug application and
the company announced that FDA supported submission … The company plans to complete its submission by mid-
2012. … FDA will not require additional
clinical efficacy or safety studies to support the company’s NDA submission … package.
11
The company
announced December 1, 2011, that FDA supported a submission of a New Drug … The company stated plans to complete its submission by mid-2012.
-
effectivehealthcare.ahrq.gov/products/form/risk-cardiovascular-disease
-
effectivehealthcare.ahrq.gov/products/form/updating-framework
-
effectivehealthcare.ahrq.gov/products/form/measurement-criteria-qdr/sead
-
effectivehealthcare.ahrq.gov/products/form/prevent-hai
-
effectivehealthcare.ahrq.gov/products/form/ped-mindfulness/sead
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/1-does-mass-spectrometric-analysis-and-therapeutic-monitoring-of-tacrolimus-as-compared-with-immunoassay-analysis-and-therapeutic-monitoring-produce-a-better-organ-survival-rate-b-fewer-rejections-c-less-nephrotoxicity-andor-
September 14, 2012 - This is a joint submission of the American Association of Clinical Chemistry and National Academy of
-
effectivehealthcare.ahrq.gov/sites/default/files/eaagleston.pdf
January 06, 2017 - The submission process was also handled through the micro-site.